Guy Georges
Guy Georges
Roche Innovation Center Munich
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ...
Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011
SAbDab: the structural antibody database
J Dunbar, K Krawczyk, J Leem, T Baker, A Fuchs, G Georges, J Shi, ...
Nucleic acids research 42 (D1), D1140-D1146, 2014
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
C Klein, A Lammens, W Schäfer, G Georges, M Schwaiger, E Mössner, ...
MAbs 5 (1), 22-33, 2013
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
G Niederfellner, A Lammens, O Mundigl, GJ Georges, W Schaefer, ...
Blood, The Journal of the American Society of Hematology 118 (2), 358-367, 2011
ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation
J Leem, J Dunbar, G Georges, J Shi, CM Deane
MAbs 8 (7), 1259-1268, 2016
SAbPred: a structure-based antibody prediction server
J Dunbar, K Krawczyk, J Leem, C Marks, J Nowak, C Regep, G Georges, ...
Nucleic acids research 44 (W1), W474-W478, 2016
The emerging role of new protein scaffold-based agents for treatment of cancer
UH Weidle, J Auer, U Brinkmann, G Georges, G Tiefenthaler
Cancer genomics & proteomics 10 (4), 155-168, 2013
Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer
UH Weidle, G Tiefenthaler, C Schiller, EH Weiss, GUY Georges, ...
Cancer genomics & proteomics 11 (1), 25-38, 2014
Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase
ME Prime, SM Courtney, FA Brookfield, RW Marston, V Walker, J Warne, ...
Journal of medicinal chemistry 54 (1), 312-319, 2011
Bispecific digoxigenin-binding antibodies for targeted payload delivery
S Metz, AK Haas, K Daub, R Croasdale, J Stracke, W Lau, G Georges, ...
Proceedings of the National Academy of Sciences 108 (20), 8194-8199, 2011
High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53
C Klein, G Georges, KP Kunkele, R Huber, RA Engh, S Hansen
Journal of Biological Chemistry 276 (40), 37390-37401, 2001
The intriguing options of multispecific antibody formats for treatment of cancer
UH Weidle, G Tiefenthaler, EH Weiss, G Georges, U Brinkmann
Cancer genomics & proteomics 10 (1), 1-18, 2013
DNA-encoded library-derived DDR1 inhibitor prevents fibrosis and renal function loss in a genetic mouse model of Alport syndrome
H Richter, AL Satz, M Bedoucha, B Buettelmann, AC Petersen, ...
ACS chemical biology 14 (1), 37-49, 2018
The H3 loop of antibodies shows unique structural characteristics
C Regep, G Georges, J Shi, B Popovic, CM Deane
Proteins: Structure, Function, and Bioinformatics 85 (7), 1311-1318, 2017
Bispecific anti-VEGF/anti-ANG-2 antibodies
M Baehner, U Brinkmann, G Georges, RA Griep, S Imhof-Jung, A Kavlie, ...
US Patent 8,268,314, 2012
ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation
B Abanades, G Georges, A Bujotzek, CM Deane
Bioinformatics 38 (7), 1877-1880, 2022
Proteases as activators for cytotoxic prodrugs in antitumor therapy
UH Weidle, G Tiefenthaler, G Georges
Cancer genomics & proteomics 11 (2), 67-79, 2014
Sphinx: merging knowledge-based and ab initio approaches to improve protein loop prediction
C Marks, J Nowak, S Klostermann, G Georges, J Dunbar, J Shi, S Kelm, ...
Bioinformatics 33 (9), 1346-1353, 2017
A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability
TE Rawson, M Rüth, E Blackwood, D Burdick, L Corson, J Dotson, ...
Journal of medicinal chemistry 51 (15), 4465-4475, 2008
Isoquinoline aminopyrazole derivatives
L Chen, G Georges, A Mertens, X Wu
US Patent 7,572,809, 2009
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20